Atomoxetine-induced hepatitis in a child

Clinical Toxicology

Volumn 45, Issue 1, 2007, Pages 51-55

  Stojanovski, Sasko D ^a   Casavant, Marcel J ^a   Mousa, Hayat M ^a   Baker, Peter ^a   Nahata, Milap C ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Atomoxetine hydrochloride; Hepatitis; Strattera

Indexed keywords

ACETYLCYSTEINE; AMINOTRANSFERASE; ATOMOXETINE; BILIRUBIN; FRESH FROZEN PLASMA; MEBENDAZOLE; PARACETAMOL; PHYTOMENADIONE; URSODEOXYCHOLIC ACID;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AMINOTRANSFERASE BLOOD LEVEL; ANAMNESIS; ARTICLE; ATTENTION DEFICIT DISORDER; BILIRUBIN BLOOD LEVEL; CASE REPORT; CHILDHOOD DISEASE; CHOLESTASIS; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG SCREENING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENTEROBIASIS; FATIGUE; FEMALE; HEPATITIS; HOSPITALIZATION; HUMAN; IMMUNOPEROXIDASE STAINING; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER TOXICITY; LOADING DRUG DOSE; MYALGIA; NECROSIS; OUTCOME ASSESSMENT; PEDIATRIC HOSPITAL; PHYSICAL EXAMINATION; PROTHROMBIN TIME; SCHOOL CHILD; SEROLOGY; SINGLE DRUG DOSE; SKIN PRURITUS; TERTIARY HEALTH CARE; VOMITING;

ADRENERGIC UPTAKE INHIBITORS; CHILD; FEMALE; HEPATITIS, TOXIC; HUMANS; LIVER; LIVER FUNCTION TESTS; NECROSIS; PROPYLAMINES; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 33847032230     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.1080/15563650600795644     Document Type: Article

References (14)

1. Caballero J, Nahata MC. Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder. Clin Ther 2003; 25:3065-3083.
2. Duff G. Committee on safety of medicine: Strattera (atomoxetine) - risk of hepatic disorders 2 February 2005. Accessed 23 June 2005, 〈http://www.mhra.gov.uk/news/February/straterra_healthprof.pdf〉
3. Eli Lilly and Company. Lilly news - financial news release. 18 April 2005. Accessed 23 June 2005. 〈http://newsroom.lilly.com/ReleaseDetail.cfm? ReleaseID=160474〉
4. Eli Lilly and Company. Strattera® (atomoxetine) prescribing information, data on file. Indianapolis, IN, 2004.
5. Lee WM. Review article - drug-induced hepatotoxicity. N Engl J Med 2003; 349:474-485.
6. Feldman M, Friedman LS, Sleisenger MH. Liver diseases caused by drugs, anesthetics, and toxins. In: Gastrointestinal and Liver Disease. Philadelphia: W.B. Saunders Company, 2002; 1403-1447.
7. Colle I, Naegels S, Hoorens A, Hautekeete M. Granulomatous hepatitis due to mebendazole. J Clin Gastroenterol 1999; 18:44-48.
8. Koppes GM, Arnett FC. Salicylate hepatotoxicity. Postgrad Med 1974; 56:193-195.
9. Danan G, Benichou C. Causality assessment of adverse reactions to drugs 1. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46:1323-1330.
10. Andrade RJ, Camargo R, Lucena MI, Gonzalez-Grande R. Causality assessment in drug-induced hepatotoxicity. Expert Opin Drug Saf 2004; 3:329-344.
11. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30:239-245.
12. Witcher JW, Long A, Smith B, Sauer JM, Heilgenstein J, Wilens T, Spencer T, Biederman J. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2003; 13:53-63.
13. De Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP 450 2C19. Psychosomatics 2006; 47:75-85.
14. Sauer JM, Ponsler GD, Mattiuz EL, Long AJ, Witcher JW, Thomasson HR, Desante KA. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug Metab Dispos 2003; 31:98-107.